Clinical Research Directory
Browse clinical research sites, groups, and studies.
Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
Sponsor: European Institute of Oncology
Summary
the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD) The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities
Official title: Identification Of Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer. Tox-DXd: a Prospective, Observational Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
84
Start Date
2025-07-31
Completion Date
2027-12-31
Last Updated
2026-01-06
Healthy Volunteers
No
Conditions
Interventions
T-DXd toxicity marker identification
to find potential predictive markers associated with T-DXd-related toxicities
Locations (1)
European Institute of Oncolgy
Milan, Italy